Overview Fundamentals API Earnings EOD API Sample Code Pricing

HLB Life Science Co. Ltd (067630 KQ) stock market data APIs

₩10500 -40(-0.4%) as of November 25, 2024
Price chart is built with Anychart

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood. Further, it is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses. The company also undertakes energy efficiency projects; and builds heating/heating system improvement projects. The company was formerly known as Energy Solutions Co., Ltd. and changed its name to HLB Life Science Co.,Ltd. in December 2015. HLB Life Science Co.,Ltd. was founded in 1998 and is headquartered in Hwaseong, South Korea.

HLB Life Science Co. Ltd Financial Data Overview

10540
10500
-
10570
10150
7700-24356.8584
1 247 640 M
46 842 K
87 628 M
590
0.4625
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '067630',
Type: 'Common Stock',
Name: 'HLB Life Science Co. Ltd',
Exchange: 'KQ',
CurrencyCode: 'KRW',
CurrencyName: 'Korean Won',
CurrencySymbol: '₩',
CountryName: 'Korea',
CountryISO: 'KR',
OpenFigi: 'BBG000C4QX33',
ISIN: 'KR7067630004',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Pharmaceuticals',
}

HLB Life Science Co. Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 87 628 M
  • EBITDA -18 367 088 640
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get HLB Life Science Co. Ltd Earnings via APIs

  • Latest Release 2024-11-12
  • EPS/Forecast NaN

Get HLB Life Science Co. Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com